AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04525820
Drug: Single high dose vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient receives either one dose orally of 140'000 IU (7 ml) of this drug once as an intervention treatment additionally to TAU or the patient receives 7 ml of the placebo Solution (7 ml) in addition to TAU
Trial: NCT04525820
Drug: Treatment as usual vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups receive the treatment as usual after the single high dose or the placebo which will be 800 IU per day
Trial: NCT03144687
Drug: Itacitinib
RxNorm normalized name: itacitinib
DrugBank: Itacitinib (DB12154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itacitinib self-administered orally once daily .
Trial: NCT03144687
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruxolitinib self-administered orally at the stable dose of \< 20 mg daily established before entering the study.
Trial: NCT01813461
Drug: 14C-labeled prodrug isavuconazonium sulfate
RxNorm normalized name: Isavuconazonium Sulfate
DrugBank: Isavuconazonium (DB06636)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: oral
Trial: NCT04744623
Drug: large dose of prednisolone plus intra-lesional of Triamcinolone Acetonide followed the systemic combination of mycophenolate mofetil (MMF), dapsone and low dose prednisolone in treatment of MMP
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 patients suffering from MMP were selected after complete diagnosis based on their clinical diagnosis and immunopathologic findings of IgG, IgA, and/or C3 targeting skin basement membranes with a linear deposition pattern refered from dermatology department. These patient were treated using large dose of prednisone 60mg daily plus intrational injection of Triamcinolone Acetonide every week until no further improvement of the lesion occurred (stage I) then the prednisolone is withdrawn gradually and substituted with using 1 g of MMF plus 50 mg dapsone till the lowest dose of prednisone could be reached (stage II).
Trial: NCT00504400
Drug: Intravitreal injection ranibizumab
RxNorm normalized name: ranibizumab Injection
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Monthly intravitreal injection of of 0.5mg ranibizumab in one eye over one year
Trial: NCT03274817
Drug: Escitalopram Pill
RxNorm normalized name: escitalopram Pill
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects randomized to group A will receive Lexapro (escitalopram), in an initial, baseline dosage of 5 mg daily.
Trial: NCT03274817
Drug: Venlafaxine Pill
RxNorm normalized name: venlafaxine Pill
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects randomized to group B will receive Effexor XR (venlafaxine extended release capsules), in an initial baseline dosage of 37.5 mg daily.
Trial: NCT00557232
Drug: bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1.25mg/month
Trial: NCT00046813
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02642900
Drug: Nystatin 100.000 units
DrugBank: Nystatin (DB00646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control group treated with nystatin
Trial: NCT00399750
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00399750
Drug: bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03218592
Drug: Maraviroc Pill
RxNorm normalized name: maraviroc Pill
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly
Trial: NCT03625128
Drug: F-18
RxNorm normalized name: FET F-18
DrugBank: Florbetaben F-18 (DB09148)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an open-label study to evaluate the performance of a novel tau imaging ligand in up to 36 subjects (12 AD, 3 FTD, 3 PSP, 3 CBS, 3 VCI and 12 HV).
Trial: NCT00489138
Drug: Ertapenem
RxNorm normalized name: Ertapenem
DrugBank: Ertapenem (DB00303)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1g a day by drip of 30 min
Trial: NCT03137537
Drug: Ivabradine
RxNorm normalized name: Ivabradine
DrugBank: Ivabradine (DB09083)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: lower heart rate in heart failure patients.
Trial: NCT02212795
Drug: Zabofloxacin 183mg
RxNorm normalized name: Marbofloxacin
DrugBank: Zabofloxacin (DB12479)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zabofloxacin 183mg single dose
Trial: NCT02212795
Drug: Levofloxacin 250mg
RxNorm normalized name: LEVOFLOXACIN 250MG TAB
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin 250mg single dose
Trial: NCT02212795
Drug: Zabofloxacin 367mg
RxNorm normalized name: Marbofloxacin
DrugBank: Zabofloxacin (DB12479)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zabofloxacin 367mg single dose
Trial: NCT03218592
Drug: Dolutegravir Pill
RxNorm normalized name: dolutegravir Pill
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly
Trial: NCT01601730
Drug: Modafinil and Escitalopram
RxNorm normalized name: Modafinil
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treatment 4: Modafinil 200 mg + Escitalopram 20 mg
Trial: NCT01601730
Drug: Modafinil
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treatment 2: Modafinil 200 mg + Escitalopram 0.
Trial: NCT01601730
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment 3: Modafinil 0 + Escitalopram 20 mg.
Trial: NCT02192359
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02192359
Drug: Irinotecan Hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02527096
Drug: dolutegravir (Tivicay®) - Phase 1
RxNorm normalized name: dolutegravir 5 MG [Tivicay]
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: • Phase 1 (8 weeks) : switch of the third agent with dolutegravir(Tivicay®) 50 mg once a day.
Trial: NCT02527096
Drug: lamivudine (Epivir®) - Phase 2
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: • Phase 2 (48 weeks): combination with lamivudine (Epivir®) 300 mg once a day + dolutegravir (Tivicay®) 50 mg once a day. Only participants with plasma HIV RNA ≤ 50 cp/mL at Week 8 will continue on phase 2.
Trial: NCT02527096
Drug: dolutegravir (Tivicay®) - Phase 2
RxNorm normalized name: dolutegravir 5 MG [Tivicay]
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: • Phase 2 (48 weeks): combination with lamivudine (Epivir®) 300 mg once a day + dolutegravir (Tivicay®) 50 mg once a day. Only participants with plasma HIV RNA ≤ 50 cp/mL at Week 8 will continue on phase 2.
Trial: NCT03179384
Drug: Ceftriaxone
RxNorm normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ceftriaxone (1g intravenous or 1g/35mL intramuscular) will be given to patients during 7 days
Trial: NCT03210766
Drug: Nabilone
RxNorm normalized name: Nabilone
DrugBank: Nabilone (DB00486)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02623023
Drug: Combigan
RxNorm normalized name: Combigan
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: brimonidine/timolol fixed combination (Combigan®, Allergan; Dublin, IRL)
Trial: NCT04513509
Drug: Atenolol, Bisoprolol, Metoprolol, Nebivolol, Propranolol, Diltiazem, Verapamil, digoxin
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Start with empirical lower dose for 3 months, and then titrate up
Trial: NCT02974504
Drug: evogliptin
RxNorm normalized name: Evogliptin
DrugBank: Evogliptin (DB12625)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: evogliptin 5mg tablet qd + placebo tablet matching to linagliptin 5mg
Trial: NCT02974504
Drug: Linagliptin
RxNorm normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: linagliptin 5 mg tablet qd + placebo tablet matching to evogliptin 5mg
Trial: NCT00981370
Drug: deferasirox
RxNorm normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Treatment starting dose of 20mg/kg/day based on subjects baseline LIC (liver iron concentration) and gradually escalate the dose to a maximum of 35 mg/kg/day based upon toxicity. Duration is up to a max of 12 months.
Trial: NCT03826615
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receive gabapentin 100mg orally for 3 times a day during the period of first and second cataract operations
Trial: NCT00777114
Drug: bortezomib, tositumomab
DrugBank: Tositumomab (DB00081)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. 0.30mg/m2 bortezomib and 50cGy 131I-tositumomab,~2. 0.30 mg/m2 bortezomib and 75 cGy 131I-tositumomab,~3. 0.60 mg/m2 bortezomib and 75 cGy 131I-tositumomab,~4. 0.90 mg/m2 bortezomib and 75 cGy 131I-tositumomab, and~5. 1.2 mg/m2 bortezomib and 75 cGy 131I-tositumomab.
Trial: NCT00492141
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cycle 2, Dose Level 1 = 100 mg/m\^2 by mouth (PO) Daily, Days 1-5 Prior to L9-NC; Cycle 3, Dose Level 2 = If the patient has no toxicity greater than grade 2, advance to 100 mg/m\^2 PO Every 12 Hours, Days 1-5 Prior to L9-NC. If the patient is not able to advance to dose level 2, the patient may continue at dose level 1 as in cycle 2; Cycle 4 and beyond = Patients will continue on dose level 1 or 2 as given in cycle 3.
Trial: NCT00492141
Drug: L9-NC
RxNorm normalized name: 9-NC
DrugBank: Rubitecan (DB06159)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycle 1 = Administered by aerosol 5 consecutive days per week for 2 weeks. A total of 10 ml of 0.4 mg/ml in an aerosol reservoir delivered over approximately 30 minutes per day given once a day, 5 days a week, for 2 weeks, followed by 2 weeks off.~Cycle 2, Dose Level 1 = Week 1, doses 1-5 preceded by temozolomide. Continue L9-NC once a day, 5 days a week, for 2 weeks, followed by 2 weeks off.~Cycle 3, Dose Level 2 = If the patient has no toxicity greater than grade 2, due to drug, during cycle 2, L9-NC may be increased to twice daily, approximately 12 hours apart. Week 1, the morning dose on days 1-5 preceded by temozolomide. L9-NC will be given twice a day, 5 days a week, for 2 weeks, followed by 2 weeks off. If the patient is not able to advance to dose level 2, the patient may continue at dose level 1 as in cycle 2.~Cycle 4 and beyond, patients will continue on dose level 1 or 2 as given in cycle 3.
Trial: NCT00262925
Drug: asparaginase
RxNorm normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IM
Trial: NCT00262925
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT00262925
Drug: vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02504164
Drug: midazolam 0.02mg/kg
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05146895
Drug: Imiquimod treatment
RxNorm normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: As an control arm, for patients with flat warts
Trial: NCT01152203
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Starting dose of 70 mg/m\^2 by vein on Days 1 and 2 of a 28 day cycle
Trial: NCT01152203
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 mg/kg by vein on Days 1 \& 15 of every 28 day cycle
Trial: NCT01310296
Drug: Lofexidine hydrochloride
RxNorm normalized name: LOFEXIDINE HYDROCHLORIDE
DrugBank: Lofexidine (DB04948)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single Dose = Solution containing 400 μg lofexidine HCl and a tracer amount of 14C lofexidine
Trial: NCT01310296
Drug: Lofexidine hydrochloride
RxNorm normalized name: LOFEXIDINE HYDROCHLORIDE
DrugBank: Lofexidine (DB04948)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single Dose = 200 μg lofexidine in phosphate-buffered saline administered intravenously via infusion pump at a rate of 1 μg/min for 200 min
Trial: NCT04760821
Drug: Trimetazidine
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine 35mg bid in patients with GFR above 60mL/min. Trimetazidine 35mg od in patients with GFR between 30 and 60mL/min.
Trial: NCT00404235
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00404235
Drug: paclitaxel albumin-stabilized nanoparticle formulation
RxNorm normalized name: Albumin-stabilized nanoparticle (130 nm)
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02105090
Drug: Sodium Chloride 0.9%
RxNorm normalized name: SODIUM CHLORIDE 0.9% INJ
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03708211
Drug: TAK-931 PIC
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-931 PICs.
Trial: NCT03708211
Drug: TAK-931 Tablet
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-931 Tablets.
Trial: NCT03708211
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esomeprazole Tablets.
Trial: NCT02760888
Drug: Tramadol
RxNorm normalized name: Tramadol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Women will receive a oral Tramadol 100mg 1 hour before the procedure
Trial: NCT00055146
Drug: ONTAK
RxNorm normalized name: Ontak
DrugBank: Denileukin diftitox (DB00004)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01373619
Drug: Ivabradine
RxNorm normalized name: Ivabradine
DrugBank: Ivabradine (DB09083)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ivabradine titrated to 7.5 mg BID
Trial: NCT04659109
Drug: glenzocimab
RxNorm normalized name: Glenzocimab
DrugBank: Glenzocimab (DB16175)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV administration as a sterile product
Trial: NCT00097695
Drug: Icatibant
RxNorm normalized name: Icatibant
DrugBank: Icatibant (DB06196)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 30 mg (3mL) subcutaneous icatibant injection in the abdominal region
Trial: NCT01508936
Drug: Reslizumab
RxNorm normalized name: Reslizumab
DrugBank: Reslizumab (DB06602)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Reslizumab administered at a dosage of 3.0 mg/kg by intravenous (iv) infusion by qualified study personnel every 4 weeks for 16 weeks (for a total of 4 doses).
Trial: NCT01498549
Drug: Atomoxetine
RxNorm normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atomoxetine 40mg and 80mg compared to the sugar pill
Trial: NCT01498549
Drug: Sugar Pill
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill compared to Atomoxetine 40mg and 80mg.
Trial: NCT03647592
Drug: Erlotinib/Gefitinib combined with Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Erlotlnib,150mg po qd/gefitinib 250mg po qd +Bevacizumab(15mg/kg),lvgtt,every 21 day ,evaluate every 2 months
Trial: NCT03980223
Drug: Doxycycline Hyclate Delayed-Release 200 mg
RxNorm normalized name: doxycycline hyclate Delayed Release Oral Capsule
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg of doxycycline taken by mouth after condomless sexual contact as post exposure prophylaxis (PEP)
Trial: NCT03091439
Drug: Dalbavancin
RxNorm normalized name: Dalbavancin
DrugBank: Dalbavancin (DB06219)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants received Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1 and on Day 8.
Trial: NCT03229499
Drug: Anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anastrozole is an aromatase inhibitor indicated for:~* adjuvant treatment of postmenopausal women with hormone receptor-positive breast cancer~* first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer~* treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy.
Trial: NCT01484340
Drug: Nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The nicotine patch be given in three phases:~* 2 weeks of patches at enrollment~* 6 weeks of patches at two-week follow-up visit~* 2 weeks of patches at two-month follow-up visit~This schedule will cover the entire 10-week course of therapy as per label instructions: 6 weeks at 21mg; 2 weeks at 14mg; and 2 weeks at 7mg.
Trial: NCT02698293
Drug: Gliolan
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: orally, 40 mg/kg 4-6 hours prior to light application
Trial: NCT01134523
Drug: Epirubicin, CTX, Paclitaxel
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epirubicin 90mg/m2 and CTX 600mg/m2 on day1 of each 21-day cycle, 4 cycles; followed by Paclitaxel 175mg/m2 on day1 of each 21-day cycle, 4 cycles.
Trial: NCT01134523
Drug: Epirubicin, Paclitaxel
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epirubicin 75mg/m2 on day1 and Paclitaxel 175mg/m2 on day2 of each 21-day cycle, 6 cycles.
Trial: NCT01214278
Drug: rTG
RxNorm normalized name: RTG
DrugBank: Ezogabine (DB04953)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA+DHA as re-esterified triglycerides (rTGs) from fish-oil; uncoated capsules (4 per day); 2016 mg n3 fatty acids daily (1008 mg EPA and 672 mg DHA)
Trial: NCT01214278
Drug: KPL
RxNorm normalized name: Immunoglobulin G4 [222-proline], anti-(human CD40 antigen) (human-Mus musculus monoclonal KPL-404 γ4-chain), disulfide with human-Mus musculus monoclonal KPL-404 κ-chain, dimer
DrugBank: Abiprubart (DB19333)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA+EPA as phospholipids from krill-oil, uncoated capsules (KPL); 7 capsules per day; 2100 mg n-3 fatty acids (1050 mg EPA and 630 mg DHA)
Trial: NCT02696798
Drug: Ixekizumab
RxNorm normalized name: Ixekizumab
DrugBank: Ixekizumab (DB11569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered SC
Trial: NCT03189706
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50mg/m\^2/day IV will be administered from day 1-5
Trial: NCT03189706
Drug: temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: (given concurrently with Irinotecan) 150mg/m\^2/day orally
Trial: NCT02664493
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Steroid pulse therapy : Methylprednisolone 0.5 g daily for 3 days, followed by a tapered dose of 60 mg per day for a period of five days.
Trial: NCT04184141
Drug: Hydroxyzine Hydrochloride
RxNorm normalized name: hydroxyzine hydrochloride
DrugBank: Hydroxyzine (DB00557)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyroxyzine hydrochloride is given to the patient one hour before surgery.
Trial: NCT04184141
Drug: Alprazolam tablet
RxNorm normalized name: Alprazolam Tablets
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alprozolam is given to the patient one hour before surgery.
Trial: NCT04131426
Drug: Remune
RxNorm normalized name: Remune
DrugBank: Remune (DB17772)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remune is intended for the dietary management of disease related malnutrition especially in patients with precachexia or cachexia due to cancer or COPD
Trial: NCT01750983
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose Escalation Group Starting Dose: 1.5 mg by vein over 90 minutes on Day 1 of each 28 day cycle.~Dose Expansion Group Starting Dose for Ipilimumab: Maximum tolerated dose (MTD) from Dose Escalation Group.
Trial: NCT01750983
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose Escalation Group Starting Dose: 10 mg by mouth on Days 1-21 of each 28 day cycle.~Dose Expansion Group Starting Dose for Lenalidomide: Maximum tolerated dose (MTD) from Dose Escalation Group.
Trial: NCT03189706
Drug: GM-CSF
RxNorm normalized name: GM-CSF
DrugBank: Regramostim (DB05386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250mcg/m2/day SC will be administered on days 6-10
Trial: NCT00216502
Drug: galantamine hydrobromide
RxNorm normalized name: Galantamine Hydrobromide
DrugBank: Galantamine (DB00674)
FDA approved: yes
EMA approved: no
PMDA approved: no